Skip to main content
Clinical Trials/NCT03099421
NCT03099421
Completed
Not Applicable

Prostatic Artery Embolization for Benign Prostatic Obstruction

Rigshospitalet, Denmark1 site in 1 country11 target enrollmentMarch 22, 2017

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Hyperplasia Prostatic
Sponsor
Rigshospitalet, Denmark
Enrollment
11
Locations
1
Primary Endpoint
Ability to void spontaneously
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

The aim of this study is to investigate the safety and efficacy of prostatic artery embolization (PAE) for patients who refuse or are not eligible for surgery with moderate-severe lower urinary tract symptoms or indwelling catheter secondary to benign prostate obstruction due to benign prostatic hyperplasia.

Detailed Description

This is a prospective study investigating the safety and efficacy of PAE for patients who refuse or are not eligible for surgery and who suffers from moderate-severe lower urinary tract symptoms or indwelling catheter secondary to benign prostatic obstruction due to benign prostatic hyperplasia. It may form the grounding for further research in the shape of a larger randomised clinical trial. Our hypothesis is that PAE will eliminate the need for indwelling catheter and improve IPSS 6 months post-procedure. 1, and 6 months follow-up. Main outcome Ability to void after removal of indwelling catheter Secondary outcomes International Prostate Symptom Score (IPSS) Quality of Life (QoL) International Index of Erectile Function (IIEF) Prostate volume Peak void flow (Qmax) Post-void residual (PVR) Classify complications according to Society of Interventional Radiology (SIR) guidelines for reporting Prostate-specific antigen (PSA)

Registry
clinicaltrials.gov
Start Date
March 22, 2017
End Date
December 14, 2018
Last Updated
7 years ago
Study Type
Interventional
Study Design
Single Group
Sex
Male

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Brian Malling

MD

Rigshospitalet, Denmark

Eligibility Criteria

Inclusion Criteria

  • Indwelling catheter secondary to benign prostatic hyperplasia (BPH) or
  • Moderate-severe Obstructive LUTS secondary to BPH refractory to medical treatment
  • Unsuitable for TURP or refuse surgery

Exclusion Criteria

  • Bladder dysfunction(and known neurological conditions affecting bladder function)
  • Urethral strictures
  • Bladder neck contracture
  • Known sphincter anomalies
  • Big bladder diverticulum or stones
  • Kidney insufficiency (eGFR \< 45)
  • Coagulation disturbances
  • Severe atheromatous or tortuosity of arteries
  • Allergy to contrast medium
  • Unable to undergo MR imaging

Outcomes

Primary Outcomes

Ability to void spontaneously

Time Frame: 6 months

Patient demonstrate the ability to void spontanously after the removal of the indwelling catheter at 6 months

Secondary Outcomes

  • PVR(1, 6 months)
  • QoL(1, 6 months)
  • PSA(1, 6 months)
  • IIEF(1, 6 months)
  • PV(1, 6 months)
  • Qmax(1, 6 months)
  • IPSS(1, 6 months)

Study Sites (1)

Loading locations...

Similar Trials